



IDS/ #5
321.03
Atty. Dkt. No. 023533-0144

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas Dag HORN et al.
Title: IMMUNOTHERAPY OF EPITHELIAL TUMORS USING
INTRALESIONAL INJECTION OF ANTIGENS THAT INDUCE
A DELAYED TYPE HYPERSENSITIVITY REACTION
Appl. No.: 10/081,185
Filing Date: 02/25/2002
Examiner: Unassigned
Art Unit: 1642

TECH CENTER 1600/2900

MAR 20 2003

RECEIVED

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

MAR 14 2003

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/081,185
Filing Date	02/25/2002
First Named Inventor	Thomas Dag Horn et al.
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	023533-0144

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	JOHNSON ET AL., "Intralesional Injection of Mumps or <i>Candida</i> Skin Test Antigens; A Novel Immunotherapy for Warts," <i>Arch. Dermatol.</i> (Apr. 2001), Vol. 137, pp. 451-455.	
	A2	PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Archives of Dermatology</i> (October 2001), full paper, 7 pages.	
	A3	PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Arch. Dermatol.</i> (October 2000), Vol. 136, pp. 1274-1275, Vignette.	
	A4	SIGNORE, Letter commenting on "Candida Immunotherapy of Warts," <i>Arch. Dermatol.</i> (Sept. 2001), Vol. 137, pp. 1250-1251.	
	A5	HARADA, "Clinical application of fungus extracts and their culture filtrates in the treatment of skin diseases: <i>Candida</i> vaccine in the treatment of warts," <i>The Japanese Journal of Dermatology (Nippon Hifuka Gakkai Zasshi)</i> (1979), Vol. 89, No. 6, pp. 397-402.	
	A6	MCCONAHY, "Common Warts: Immunity as a Result of Therapy," <i>CUTIS</i> (February 1976), Vol. 17, pp. 301-304.	
	A7	GREENSHER, "The Treatment of Warts with Mumps Skin Test Antigen," <i>Society of Teachers of Family Medicine</i> , 9 pages.	
	A8	GREENSHER, "Treatment of Laryngeal Papillomas with Mumps Skin Test Antigen," <i>The Lancet</i> (October 25, 1980), pp. 920-921.	
	A9	NAYLOR ET AL., "Contact immunotherapy of resistant warts," <i>Journal of the American Academy of Dermatology</i> (Oct. 1988), Vol., 19, No. 4, pp. 679-683, Abstract.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 14, 2003

FOLEY & LARDNER
Customer Number: 22428



22428


PATENT TRADEMARK OFFICE

Telephone: (202) 672-5483

Facsimile: (202) 672-5399

By Jayme A. Huleatt

Jayme A. Huleatt
Attorney for Applicants
Registration No. 34,485



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Applicati n Numb r	10/081,185
Filing Date	02/25/2002
First Named Inv ntor	Thomas Dag Horn et al.
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	023533-0144

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A10	PARSAD ET AL., "Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children," <i>Pediatric Dermatology</i> (Jul.-Aug. 2001), Vol. 18, No. 4, pp. 349-352, Abstract.	
	A11	AVENTIS PASTEUR, "Mumps Skin Test Antigen USP," Product Information Brochure as of February 1997, 2 pages.	
	A12	CANDIN®, Package Insert Text, 8 pages.	

RECEIVED

MAR 20 2003

TECH CENTER 1600/2900

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.